Associate Director - Oncology Field Reimbursement Strategy

Johnson & Johnson Co.; Horsham (PA); On-site; USD 127,000 - 219,000; Full time

Benefits offered by this job

Long-term incentive program

Comprehensive benefits

Job summary

Johnson & Johnson Innovative Medicine seeks an Associate Director, Field Reimbursement Strategy & Execution-Oncology, to lead three direct reports and shape FRM strategy for the Oncology portfolio. You will align portfolio priorities with brand, market access, patient experience, analytics and field leadership to improve access and patient outcomes.

The role emphasizes strategic thinking, disciplined execution, and transformation across portfolio strategy, launch readiness, and

Qualifications

• Strategic and portfolio leadership across oncology FRM.
• Deep knowledge of access, reimbursement and market dynamics.
• Proven ability to coach and develop teams.
• Ability to influence across a complex matrix and drive results.
• Strong data, analytics, and technology fluency for decision support.

Responsibilities

• Lead FRM strategy and operating model across Oncology portfolio.
• Define field actions, launch readiness, and account prioritization.
• Measure impact with dashboards and analytics, guide technology enablement.
• Build capability and run national meetings with cross-functional partners.
• Coach three direct reports and foster inclusive, high-performing culture.

Skills

Strategic leadership

Portfolio leadership

Market access

People leadership

Cross-functional influence

Operational excellence

Data analytics

Communication

Patient focus

Job description

Johnson & Johnson Innovative Medicine seeks an Associate Director, Field Reimbursement Strategy & Execution-Oncology, to lead three direct reports and shape FRM strategy for the Oncology portfolio. You will align portfolio priorities with brand, market access, patient experience, analytics and field leadership to improve access and patient outcomes.

The role emphasizes strategic thinking, disciplined execution, and transformation across portfolio strategy, launch readiness, and